Skip to main content
CHEMCLIN DIAGNOSTICS CO., LTD. logo

CHEMCLIN DIAGNOSTICS CO., LTD. — Investor Relations & Filings

Ticker · 688468 ISIN · CNE100005311 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2023-09-18 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688468

About CHEMCLIN DIAGNOSTICS CO., LTD.

https://www.chemclin.com/

CHEMCLIN DIAGNOSTICS CO., LTD. specializes in the research, development, and manufacturing of in vitro diagnostic systems and reagents. The company is primarily recognized for its proprietary Light-initiated Chemiluminescent Assay (LiCA) technology, a homogeneous chemiluminescence platform that eliminates the need for washing steps, thereby enhancing testing efficiency and precision. Its product portfolio includes fully automated immunoassay analyzers and a comprehensive range of diagnostic kits covering infectious diseases, cardiac markers, thyroid function, tumor markers, and reproductive health. By integrating advanced biotechnology with automated instrumentation, the company provides clinical laboratories and medical institutions with high-sensitivity diagnostic solutions designed to improve patient care and laboratory workflow.

Recent filings

Filing Released Lang Actions
科美诊断技术股份有限公司关于自愿披露公司获得发明专利的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a new invention patent certificate from the National Intellectual Property Office. It details the patent's basic information and its impact on the company. There is no financial data, no mention of financial results, no regulatory filings, no meeting materials, no voting results, no management changes, no legal proceedings, no capital changes, and no other report types. This is a regulatory announcement about intellectual property rights, which does not fit into any specific financial report category. Therefore, it falls under the fallback category of Regulatory Filings (RNS). The document length is short and it is a standalone announcement, not a report or presentation.
2023-09-18 Chinese
中信证券股份有限公司关于科美诊断技术股份有限公司2023年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2023 Half-Year Continuous Supervision Tracking Report" issued by CITIC Securities as the sponsor institution for a company listed on the STAR Market. It references regulatory frameworks related to securities issuance and listing, continuous supervision, and compliance with Shanghai Stock Exchange rules. The content includes detailed descriptions of ongoing supervision activities, risk assessments, financial data for the first half of 2023, and operational and governance reviews. The document contains substantive financial data and analysis for the half-year period (January to June 2023), including income, profit, cash flow, and financial ratios. It is not merely an announcement or a brief summary but a comprehensive report covering the company's performance and risks for the interim period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2023
2023-09-13 Chinese
科美诊断技术股份有限公司关于召开2023年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2023 half-year performance explanation meeting (业绩说明会) for investors. It mentions the date, time, location, and participation method for the meeting, which is a typical investor presentation event. The document references the 2023 half-year report but does not contain actual financial data or detailed financial analysis itself. The document length is short (1478 characters) and serves as a notice for the upcoming investor presentation rather than the presentation or report itself. Therefore, it fits the category of Investor Presentation (IP).
2023-09-12 Chinese
科美诊断技术股份有限公司关于自愿披露公司获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company about receiving a medical device registration certificate from the Beijing Drug Administration. It details the product registration information, expected impact on the company, and risk warnings. There is no financial data, no mention of annual or quarterly reports, no voting results, no management changes, no legal proceedings, or other report types. The document is short (757 characters) and serves as a regulatory announcement about product registration and its potential impact. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-08-31 Chinese
科美诊断技术股份有限公司第二届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a supervisory board announcement regarding the approval of the company's 2023 semi-annual report and a special report on the use of raised funds. It confirms the legality and accuracy of the semi-annual report and the proper use of funds, but does not contain the full financial statements or detailed financial data itself. It references the actual semi-annual report and the special report as being disclosed elsewhere (Shanghai Stock Exchange website). The document length is short (1138 characters) and serves as an announcement of the supervisory board's review and approval rather than the report itself. Therefore, it fits best as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or Annual Report (10-K).
2023-08-29 Chinese
科美诊断技术股份有限公司独立董事关于第二届董事会第四次会议相关议案的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on a specific agenda item discussed at a board meeting held on August 28, 2023. The agenda item concerns a special report on the storage and use of raised funds for the half-year 2023 period. The document is short (1260 characters) and primarily provides an independent opinion rather than the full report itself. It references regulatory guidelines and confirms compliance but does not contain substantive financial data or the full report. This fits the profile of a Regulatory Filing (RNS) as it is a formal regulatory announcement related to governance and compliance rather than a full financial report or management report.
2023-08-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.